FDA Approved: STEGLUJAN — Original Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved the original application for Steglujan, a fixed-dose combination of ertugliflozin and sitagliptin, for improving glycemic control in adults with ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• STEGLUJAN (ERTUGLIFLOZIN AND SITAGLIPTIN)

Snippet

ORIG AP for STEGLUJAN (ERTUGLIFLOZIN AND SITAGLIPTIN)